Nafarelin
Also known as: Synarel, Nafarelin Acetate
Nafarelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist that initially stimulates then suppresses LH and FSH production. Research applications focus on endometriosis treatment, precocious puberty management, and reproductive system modulation studies.
Nafarelin is a 1322.47 g/mol research peptide. Nafarelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist that initially stimulates then suppresses LH and FSH production. Research applications focus on endometriosis treatment, precocious puberty management, and reproductive system modulation studies.
Also called: Synarel, Nafarelin Acetate
1322.47 g/mol
Molecular Weight
Daltons
3
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
200-400
Typical Dose
mcg
Overview
Nafarelin acts as a potent synthetic analog of naturally occurring GnRH, demonstrating approximately 200-fold greater potency than the native hormone. The compound binds to GnRH receptors in the anterior pituitary gland, triggering an initial surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. With continued administration, receptor downregulation occurs, leading to profound suppression of gonadal steroid production. This biphasic response makes nafarelin valuable for research into reproductive endocrinology, hormone-dependent conditions, and therapeutic applications requiring controlled gonadal suppression. The peptide's unique pharmacological profile allows researchers to study both acute hormonal stimulation and chronic suppression effects within controlled experimental frameworks.
Key Takeaways: Nafarelin
- Strongest evidence supports Nafarelin for endometriosis research applications and precocious puberty studies
- Research doses typically range from 200 to 400 mcg via intranasal
- 3 benefits with strong evidence, 3 moderate, 0 preliminary
- Half-life: 3-4 hours
- 4 cited research studies in this guide
Mechanism of Action
Nafarelin binds to GnRH receptors on gonadotroph cells in the anterior pituitary, initially causing release of stored LH and FSH. Continuous exposure leads to receptor desensitization and downregulation, resulting in suppressed gonadotropin secretion and subsequent reduction in testosterone and estradiol production. This creates a reversible medical castration state through hypothalamic-pituitary-gonadal axis suppression.
Research Benefits
Nafarelin at a Glance
Nafarelin binds to GnRH receptors on gonadotroph cells in the anterior pituitary, initially causing release of stored LH and FSH.
Endometriosis Research Applications
Strong EvidenceEffectively suppresses estrogen production to create a hypoestrogenic state, allowing researchers to study endometrial tissue regression and pain reduction mechanisms in experimental models.
Precocious Puberty Studies
Strong EvidenceDelays pubertal progression by suppressing gonadotropin release, providing researchers with models to study normal versus accelerated pubertal development pathways.
Reproductive Hormone Research
Strong EvidenceCreates controlled hormonal environments for studying the effects of gonadal steroid withdrawal and replacement in various physiological systems.
Fertility Research Applications
Moderate EvidenceEnables controlled ovarian suppression studies and investigation of reproductive cycle manipulation in research settings.
Hormone-Dependent Tumor Models
Moderate EvidenceProvides researchers with a tool to study the growth patterns of hormone-sensitive tissues under various estrogen and testosterone suppression conditions.
Bone Metabolism Research
Moderate EvidenceAllows investigation of bone density changes and calcium metabolism under conditions of sex hormone deficiency.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Endometriosis research | 200–400 mcg | intranasal |
| Precocious puberty studies | 400–1600 mcg | intranasal |
Frequency
Twice daily (morning and evening)
Timing
12 hours apart for consistent plasma levels
Cycle Length
3-6 months depending on research protocol
Research Notes
- 1Intranasal administration requires proper technique for optimal absorption
- 2Initial flare effect may occur in first 2-4 weeks
- 3Baseline hormone levels should be established before treatment
- 4For research purposes only - not for human consumption
Reconstitution Guide
Standard Reconstitution
Vial Size
0 mg
Bacteriostatic Water
0 mL
Concentration
NaN mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Nafarelin vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 0 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at Store at room temperature (20-25°C). 36 months unopened, 30 days after first use.
Storage Temperature
Store at room temperature (20-25°C)
Shelf Life
36 months unopened, 30 days after first use
Important Notes
- •Available as nasal spray formulation - no reconstitution required
- •Protect from light and excessive heat
- •Prime pump before first use
- •Clean nasal applicator regularly to prevent contamination
Nafarelin Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Nafarelin Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Hot flashes and vasomotor symptoms
- !Decreased libido and sexual dysfunction
- !Vaginal dryness and atrophy
- !Mood changes and depression
- !Headache and dizziness
- !Nasal irritation and rhinitis
- !Bone density reduction with prolonged use
- !Sleep disturbances
- !Joint pain and muscle aches
- !Weight gain or loss
Potential Interactions
- ⚡Alcohol may exacerbate vasomotor symptoms and mood effects
- ⚡Calcium and vitamin D supplementation may be necessary due to bone density effects
- ⚡Hormone replacement therapy can counteract intended effects
- ⚡Nasal decongestants may affect absorption when used intranasally
- ⚡CYP enzyme inducers may theoretically alter metabolism
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Nafarelin versus danazol in the treatment of endometriosis
Comparative study demonstrated nafarelin's efficacy in reducing endometriotic lesions with different side effect profile compared to danazol treatment.
Long-term treatment of central precocious puberty with nafarelin
Long-term follow-up study showed effective pubertal suppression with nafarelin treatment in children with central precocious puberty.
Bone mineral density in women treated with nafarelin for endometriosis
Research documented significant bone mineral density changes during nafarelin treatment, highlighting the need for monitoring in extended therapy.
Pharmacokinetics of nafarelin following intranasal administration
Detailed pharmacokinetic analysis of intranasal nafarelin absorption, distribution, and elimination in clinical subjects.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Nafarelin initially stimulates GnRH receptors, causing an initial hormone surge. Continued use leads to receptor downregulation and desensitization, ultimately suppressing LH and FSH production, which reduces testosterone and estrogen levels.
Both are GnRH agonists, but nafarelin is administered intranasally while leuprolide is typically injected. Nafarelin has a shorter half-life requiring twice-daily dosing, whereas leuprolide formulations can provide monthly or longer suppression.
Initial hormone suppression occurs within 2-4 weeks of starting treatment. Full suppression typically develops within 4-6 weeks, though an initial flare effect may occur in the first weeks of treatment.
Yes, nafarelin effects are reversible. Hormone levels typically begin recovering within 2-3 months after discontinuing treatment, with full recovery usually occurring within 6-12 months.
Primary research applications include endometriosis studies, precocious puberty research, reproductive hormone investigations, and studies requiring controlled gonadal suppression to examine hormone-dependent processes.
Yes, prolonged nafarelin use can significantly reduce bone mineral density due to estrogen suppression. Research protocols typically include calcium and vitamin D supplementation and bone density monitoring.
Nafarelin is administered intranasally using a metered-dose spray. Proper technique includes clearing nasal passages, positioning the bottle correctly, and avoiding sniffing immediately after administration.
The flare effect refers to the initial increase in hormone levels that occurs during the first 2-4 weeks of treatment before suppression takes effect. This can temporarily worsen hormone-dependent symptoms in research models.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.